Adjuvant chemotherapy and immunotherapy for colorectal cancer: preliminary communication
- PMID: 7014886
- PMCID: PMC1437544
- DOI: 10.1177/014107688007300308
Adjuvant chemotherapy and immunotherapy for colorectal cancer: preliminary communication
Abstract
Following surgical resection of Dukes' B or C colorectal cancers 72 patients have been randomly allocated to receive: 5-fluorouracil; or 5-fluorouracil and levamisole; or no treatment. Adjuvant treatment was continued for one year. 66 patients remain evaluable for up to 24 months. Preliminary results show no significant differences in survival or recurrence rates. Two patients receiving 5-fluorouracil and levamisole developed severe, but reversible, neutropenia. Other side effects were uncommon.
References
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
